MT1-MMP Expression Levels and Catalytic Functions Dictate LDL Receptor-Related Protein-1 Ligand Internalization Capacity in U87 Glioblastoma Cells.

Abstract

Modulations in cell surface receptor ectodomain proteolytic shedding impact on receptor function and cancer biomarker expression. As such, heavily pursued therapeutic avenues have exploited LDL receptor-related protein-1 (LRP-1)-mediated capacity in internalizing Angiopep-2 (An2), a brain-penetrating peptide that allows An2-drug conjugates to cross the blood-brain tumor barrier (BBTB). Given that LRP-1 is proteolytically shed from the cell surface through matrix metalloproteinase (MMP) activity, the balance between MMP expression/function and LRP-1-mediated An2 internalization is unknown. In this study, we found that membrane type-1 (MT1)-MMP expression increased from grade 1 to 4 brain tumors, while that of LRP-1 decreased inversely. MMP pharmacological inhibitors such as Ilomastat, Doxycycline and Actinonin increased in vitro An2 internalization by up to 2.5 fold within a human grade IV-derived U87 glioblastoma cell model. Transient siRNA-mediated MT1-MMP gene silencing resulted in increased basal An2 cell surface binding and intracellular uptake, while recombinant MT1-MMP overexpression reduced both cell surface LRP-1 expression as well as An2 internalization. The addition of Ilomastat to cells overexpressing recombinant MT1-MMP restored LRP-1 expression at the cell surface and An2 uptake to levels comparable to those observed in control cells. Collectively, our data suggest that MT1-MMP expression status dictates An2-mediated internalization processes in part by regulating cell surface LRP-1 functions. Such evidence prompts preclinical evaluations of combined MMP inhibitors/An2-drug conjugate administration to potentially increase the treatment of high-MT1-MMP-expressing brain tumors.

• Authors: Jonathan Pratt, Khadidja Haidara, Borhane Annabi
• Journal: International journal of molecular sciences (Int J Mol Sci) Vol. 23 Issue 22 (Nov 17 2022) ISSN: 1422-0067 [Electronic] Switzerland
• PMID: 36430705 (Publication Type: Journal Article)

Chemical References

• ilomastat
• Ligands
• Low Density Lipoprotein Receptor-Related Protein-1
• Matrix Metalloproteinase 14
• Matrix Metalloproteinase Inhibitors
• Angiopep-2

Topics

• Humans
• Brain Neoplasms (drug therapy, genetics, pathology)
• Cell Line, Tumor
• Glioblastoma (metabolism)
• Ligands
• Low Density Lipoprotein Receptor-Related Protein-1 (metabolism)
• Matrix Metalloproteinase 14 (genetics, metabolism)
• Matrix Metalloproteinase Inhibitors (pharmacology)